Characteristics of the 157 patients with FLT3-ITD-positive AML according to MRD status after Cy2 (n = 142)
| Clinical and genetic variables . | All patients (N = 157) . | MRDneg Cy2 (n = 111) . | MRDpos Cy2 (n = 31) . | P value . |
|---|---|---|---|---|
| Age (y), median (range) | 54 (20-70) | 54 (20-70) | 51 (25-70) | .229 |
| Sex, n (%) | ||||
| Male | 69 (44) | 45 (40) | 17 (55) | .219 |
| Female | 88 (56) | 66 (60) | 14 (45) | |
| WBC (109/L) | ||||
| Median (range) | 51.8 (0.5-356.4) | 46.3 (0.5-356.4) | 67.8 (1.1-279.6) | .056 |
| Missing | 2 | 1 | 0 | |
| Hemoglobin (g/dL) | ||||
| Median (range) | 9.3 (4.1-15.0) | 9.2 (4.1-15.0) | 9.6 (5.6-13.8) | .553 |
| Missing | 2 | 1 | 0 | |
| Platelets (109/L) | ||||
| Median (range) | 60 (5-352) | 56 (5-352) | 59 (13-148) | .547 |
| Missing | 2 | 1 | 0 | |
| BM blasts (%) | ||||
| Median (range) | 81 (0-100) | 85 (0-100) | 83 (20-100) | .564 |
| Missing | 18 | 13 | 5 | |
| PB blasts (%) | ||||
| Median (range) | 46 (0-99) | 42 (0-99) | 53 (0-98) | .364 |
| Missing | 10 | 8 | 0 | |
| AML type, n (%) | ||||
| De novo | 142 (90) | 100 (90) | 29 (94) | .388 |
| Secondary | 8 (5) | 6 (5) | 0 | |
| Therapy-related | 7 (5) | 5 (5) | 2 (6) | |
| ELN 2017 risk classification, n (%) | ||||
| Favorable | 31 (20) | 22 (20) | 4 (13) | <.001 |
| Intermediate | 100 (64) | 79 (72) | 15 (48) | |
| Adverse | 25 (16) | 9 (8) | 12 (39) | |
| Missing | 1 | 1 | 0 | |
| FLT3-ITD AR, n (%) | ||||
| Low (<0.5) | 67 (43) | 47 (42) | 12 (39) | .837 |
| High (≥0.5) | 90 (57) | 64 (58) | 19 (61) | |
| FLT3-TKD, n (%) | ||||
| Yes | 6 (4) | 2 (2) | 3 (10) | .069 |
| No | 151 (96) | 109 (98) | 28 (90) | |
| Mutated NPM1, n (%) | ||||
| Yes | 111 (71) | 90 (81) | 12 (39) | <.001 |
| No | 46 (29) | 21 (19) | 19 (61) |
| Clinical and genetic variables . | All patients (N = 157) . | MRDneg Cy2 (n = 111) . | MRDpos Cy2 (n = 31) . | P value . |
|---|---|---|---|---|
| Age (y), median (range) | 54 (20-70) | 54 (20-70) | 51 (25-70) | .229 |
| Sex, n (%) | ||||
| Male | 69 (44) | 45 (40) | 17 (55) | .219 |
| Female | 88 (56) | 66 (60) | 14 (45) | |
| WBC (109/L) | ||||
| Median (range) | 51.8 (0.5-356.4) | 46.3 (0.5-356.4) | 67.8 (1.1-279.6) | .056 |
| Missing | 2 | 1 | 0 | |
| Hemoglobin (g/dL) | ||||
| Median (range) | 9.3 (4.1-15.0) | 9.2 (4.1-15.0) | 9.6 (5.6-13.8) | .553 |
| Missing | 2 | 1 | 0 | |
| Platelets (109/L) | ||||
| Median (range) | 60 (5-352) | 56 (5-352) | 59 (13-148) | .547 |
| Missing | 2 | 1 | 0 | |
| BM blasts (%) | ||||
| Median (range) | 81 (0-100) | 85 (0-100) | 83 (20-100) | .564 |
| Missing | 18 | 13 | 5 | |
| PB blasts (%) | ||||
| Median (range) | 46 (0-99) | 42 (0-99) | 53 (0-98) | .364 |
| Missing | 10 | 8 | 0 | |
| AML type, n (%) | ||||
| De novo | 142 (90) | 100 (90) | 29 (94) | .388 |
| Secondary | 8 (5) | 6 (5) | 0 | |
| Therapy-related | 7 (5) | 5 (5) | 2 (6) | |
| ELN 2017 risk classification, n (%) | ||||
| Favorable | 31 (20) | 22 (20) | 4 (13) | <.001 |
| Intermediate | 100 (64) | 79 (72) | 15 (48) | |
| Adverse | 25 (16) | 9 (8) | 12 (39) | |
| Missing | 1 | 1 | 0 | |
| FLT3-ITD AR, n (%) | ||||
| Low (<0.5) | 67 (43) | 47 (42) | 12 (39) | .837 |
| High (≥0.5) | 90 (57) | 64 (58) | 19 (61) | |
| FLT3-TKD, n (%) | ||||
| Yes | 6 (4) | 2 (2) | 3 (10) | .069 |
| No | 151 (96) | 109 (98) | 28 (90) | |
| Mutated NPM1, n (%) | ||||
| Yes | 111 (71) | 90 (81) | 12 (39) | <.001 |
| No | 46 (29) | 21 (19) | 19 (61) |
TKD, tyrosine kinase domain.